|Dr. George A. Scangos||Pres, CEO & Director||785.83k||N/A||1948|
|Dr. Klaus Frueh||Co-Founder & Scientific Advisor||177.66k||N/A||1960|
|Mr. Howard Horn||CFO & Sec.||599.25k||N/A||1977|
|Dr. Herbert W. Virgin IV||Exec. VP of Research & Chief Scientific Officer||949.9k||N/A||1956|
|Dr. Jay Parrish||Co-Founder & Chief Bus. Officer||N/A||N/A||1975|
|Dr. Lawrence Corey||Co-Founder & Scientific Advisor||N/A||N/A||N/A|
|Dr. Louis J. Picker||Co-Founder & Scientific Advisor||N/A||N/A||N/A|
|Dr. Michael E. Kamarck||Chief Technology Officer||N/A||N/A||1951|
|Mr. Steven J. Rice||Chief Admin. Officer||N/A||N/A||N/A|
|Dr. Neera Dahiya Ravindran M.D., MBA||VP and Head of Investor Relations & Strategic Communications||N/A||N/A||N/A|
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc.’s ISS governance QualityScore as of 2 December 2020 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 9; Compensation: 9.